Legato Capital Management LLC Has $2.53 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Legato Capital Management LLC increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 3.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 45,656 shares of the company’s stock after purchasing an additional 1,496 shares during the quarter. Legato Capital Management LLC owned approximately 0.12% of Tarsus Pharmaceuticals worth $2,528,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in TARS. Bleakley Financial Group LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $323,000. Jennison Associates LLC increased its stake in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after acquiring an additional 321,552 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Tarsus Pharmaceuticals by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company’s stock worth $449,000 after buying an additional 789 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $249,000. Finally, R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $53,000. Institutional investors own 90.01% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on TARS. Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Guggenheim reaffirmed a “buy” rating on shares of Tarsus Pharmaceuticals in a research note on Monday. The Goldman Sachs Group lifted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Finally, Barclays upped their target price on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $56.00.

Tarsus Pharmaceuticals Stock Down 1.0 %

Tarsus Pharmaceuticals stock opened at $51.22 on Wednesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The business has a 50-day moving average of $52.05 and a 200-day moving average of $41.22. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.